Abstract：
Cardiotoxicity associated with chemotherapy, also known as Cancer Therapy-Related Cardiac Dysfunction (CTRCD), affects 10% of patients undergoing chemotherapy and is the most undesirable side effect of chemotherapy. Over time, it is anticipated that there would be an increase in the number of cancer patients receiving treatments that could harm their cardiovascular systems. Physicians should choose whether to continue, halt, delay, or reduce the dose of chemotherapeutic drugs to reduce the impact of cardiotoxicity. Cardiotoxicity screening and diagnosis need a variety of methods, primarily echocardiography to evaluate Left Ventricular Ejection Fraction (LVEF) and Global Longitudinal Strain (GLS). Depending on the clinical state, these procedures may be carried out prior to, during, or following chemotherapy. It\'s critical to reduce cardiovascular risk factors and offer advice on leading a healthy lifestyle before giving cancer patients medicines. There are a lot of cancer treatment facilities all around the world that don\'t have evidence-based perspective cardiotoxicity scores to stratify the risk of cardiovascular problems caused by cancer therapy. Additionally, comorbid conditions like diabetes and hypertension are frequently present in cancer patients, which can have a significant impact on clinical outcomes and cancer treatment. Therefore, this article aims to discuss assessment methods, clinical practice guidance, and prevention of CTRCD.
摘要：
与化疗相关的心脏毒性，也称为癌症治疗相关的心脏功能障碍（CTRCD），影响10％的化疗患者，是化疗最不良的副作用。随着时间的推移,预计接受可能损害其心血管系统的治疗的癌症患者数量将会增加。医生应该选择是否继续，halt,延迟,或减少化疗药物的剂量，以减少心脏毒性的影响。心脏毒性的筛查和诊断需要多种方法,主要超声心动图评估左心室射血分数（LVEF）和整体纵向应变（GLS）。根据临床情况,这些程序可以在之前进行，during,或化疗后。在给癌症患者服用药物之前，减少心血管危险因素并提供健康生活方式的建议至关重要。世界各地有许多癌症治疗机构没有基于证据的心脏毒性评分来分层癌症治疗引起的心血管问题的风险。此外,癌症患者中经常出现糖尿病和高血压等合并症，这可能对临床结果和癌症治疗产生重大影响。因此,本文旨在讨论评估方法，临床实践指导,CTRCD的预防。
